; Claret-like model for describing CTS. No resistance to drug treatment. Independent additive effect of the two drugs. M3 method for BLQ. Additive error $SIZES LIM6=2000 $PROBLEM Model for SLD(t) $INPUT CCOM,ID, TIME, ;in day DV, ;SLD in mm BQL, ;the LLOQ is 5 mm CB, ;exposure to carboplatin (per-cycle average AUC) G, ;exposure to gemcitabine (per-cycle average AUC) EVID, FLG, ;FLG=2 for SLD data, FLG=1 for exposure-related entries CMT ;CMT=1 for SLD data $DATA Simulated_SLD.csv IGNORE=C $SUBROUTINE ADVAN6 TOL=3 $MODEL ;Tumour COMP = (TUMOUR, DEFOBS) $PK KG = THETA(1)*EXP(ETA(1)) ;tumour growth rate constant (1/day) KD0 = THETA(2)*EXP(ETA(2)) ;carboplatin related death rate constant (1/day/AUC0) KD1 = THETA(3)*EXP(ETA(2)) ;gemcitabine related death rate constant (1/day/AUC1) IBASE = THETA(4)*EXP(ETA(3)) ;baseline SLD (m) FADD = THETA(5) ;SD of additive error (mm) ; ==== SLD baseline ==== A_0(1) = IBASE*1000 ; Backward interpolation of exposure-related data IF(NEWIND.NE.2) OCB=CB IF(NEWIND.NE.2) OG=G E0 = OCB E1 = OG OCB=CB OG=G $DES ; Model for dSLD(t) DADT(1) = KG/1000 * A(1) - (KD0/1000 * E0 + KD1/100 * E1) * A(1) $ERROR LLOQ = 5 ;5 mm is LLOQ IPRED = A(1) W = FADD ;SD of additive unexpained variability ; Probability of SLD